These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 17934818)
1. The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells. Zvibel I; Bar-Zohar D; Kloog Y; Oren R; Reif S Dig Dis Sci; 2008 Apr; 53(4):1048-53. PubMed ID: 17934818 [TBL] [Abstract][Full Text] [Related]
2. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579 [TBL] [Abstract][Full Text] [Related]
3. Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation. Neeman R; Abramovitch S; Sharvit E; Elad-Sfadia G; Haklai R; Kloog Y; Reif S Dig Dis Sci; 2014 Oct; 59(10):2462-9. PubMed ID: 24942325 [TBL] [Abstract][Full Text] [Related]
4. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid. Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024 [TBL] [Abstract][Full Text] [Related]
5. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. Clarke HC; Kocher HM; Khwaja A; Kloog Y; Cook HT; Hendry BM J Am Soc Nephrol; 2003 Apr; 14(4):848-54. PubMed ID: 12660318 [TBL] [Abstract][Full Text] [Related]
6. Novel Ras antagonist blocks human melanoma growth. Jansen B; Schlagbauer-Wadl H; Kahr H; Heere-Ress E; Mayer BX; Eichler H; Pehamberger H; Gana-Weisz M; Ben-David E; Kloog Y; Wolff K Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14019-24. PubMed ID: 10570191 [TBL] [Abstract][Full Text] [Related]
7. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255 [TBL] [Abstract][Full Text] [Related]
8. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. Nevo Y; Aga-Mizrachi S; Elmakayes E; Yanay N; Ettinger K; Elbaz M; Brunschwig Z; Dadush O; Elad-Sfadia G; Haklai R; Kloog Y; Chapman J; Reif S PLoS One; 2011 Mar; 6(3):e18049. PubMed ID: 21445359 [TBL] [Abstract][Full Text] [Related]
9. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. Gana-Weisz M; Haklai R; Marciano D; Egozi Y; Ben-Baruch G; Kloog Y Biochem Biophys Res Commun; 1997 Oct; 239(3):900-4. PubMed ID: 9367867 [TBL] [Abstract][Full Text] [Related]
10. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677 [TBL] [Abstract][Full Text] [Related]
11. Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. Santen RJ; Lynch AR; Neal LR; McPherson RA; Yue W Anticancer Drugs; 2006 Jan; 17(1):33-40. PubMed ID: 16317288 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats. da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500 [TBL] [Abstract][Full Text] [Related]
13. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma. Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020 [TBL] [Abstract][Full Text] [Related]